Author

A.-L. Borresen-Dale

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Assay:bulk RNA-seq· 3 Research Focus:chromatin & epigenetic regulation· 3 Assay:DNA methylation· 3 Approach:statistical model· 3 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

J. Ankill· 2 shared K. K. Sahlberg· 2 shared O. C. Lingjaerde· 2 shared O. Engebraaten· 2 shared T. Fleischer· 2 shared V. N. Kristensen· 2 shared A. B. Brinkman· 1 shared A. Butler· 1 shared

Activity by Year

2018-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Ankill

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

An integrated 'omics approach highlights the role of epigenetic events to explain and predict response to neoadjuvant chemotherapy and bevacizumab

T. Fleischer, M. H. Haugen, J. Ankill, L. Silwal-Pandit, A.-L. Borresen-Dale, I. Hedenfalk, T. Hatschek, J. Tost, O. Engebraaten, V. N. Kristensen

This study uses an integrated omics approach to show that DNA methylation at enhancer CpGs can predict response to neoadjuvant chemotherapy and bevacizumab in ER-positive patients.

bioRxiv · Jul 6, 2022 · PreprintCancer Biology

Crosstalk between microRNA expression and DNA methylation drive the hormone-dependent phenotype of breast cancer

M. R. Aure, T. Fleischer, S. Bjorklund, J. Ankill, J. A. Castro-Mondragon, Oslo Breast Cancer Research Consortium (OSBREAC), A.-L. Borresen-Dale, K. K. Sahlberg, A. Mathelier, X. Tekpli, V. N. Kristensen

The paper investigates how microRNA expression and DNA methylation interact to drive hormone-dependent breast cancer phenotypes by analyzing two breast cancer cohorts.

Genome Medicine · Apr 29, 2021Peer-reviewedCancer Biology

Breast tumors escape endocrine therapy by ER-independent mechanisms triggered by the coordinated activities of HER2/HER3 and deacetylated FOXA1

S. Gilfillan, S. Wang, M. R. Katika, J. H. Norum, H. Bergholtz, E. Fiorito, S. Nordhagen, Y. Sharma, S. Singh, V. S. Somisety, A.-M. Fosdahl, S. Nord, O. Engebraaten, O. C. Lingjaerde, A.-L. Borresen-Dale, , A. Hurtado-Rodriguez

This study shows that HER2/HER3 signaling and FOXA1 deacetylation drive ER-independent growth in hormone-resistant breast tumors by altering FOXA1 chromatin binding and function.

bioRxiv · Sep 22, 2020 · PreprintCancer Biology

Partially methylated domains are hypervariable in breast cancer and fuel widespread CpG island hypermethylation

A. B. Brinkman, S. Nik-Zainal, F. Simmer, F. G. Rodriguez-Gonzalez, M. Smid, L. B. Alexandrov, A. Butler, S. Martin, H. Davies, G. Dominik, X. Zou, M. Ramakrishna, J. Staaf, M. Ringner, A. Sieuwerts, , H. G. Stunnenberg

The paper shows PMDs are hypervariable in breast cancer and drive CGI hypermethylation, but do not significantly repress cancer genes.

bioRxiv · Nov 15, 2018Cancer Biology

Intra-tumor heterogeneity defines treatment-resistant HER2+ breast tumors

I. H. Rye, A. Trinh, A. Saetersdal, D. Nebdal, O. C. Lingjaerde, V. Almendro, K. Polyak, A.-L. Borresen-Dale, A. Helland, F. Markowetz, H. G. Russnes

This study examines how intra-tumor heterogeneity in HER2 expression and copy number affects treatment outcomes in HER2+ breast cancer patients.

bioRxiv · Apr 18, 2018Cancer Biology